CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Overview of approved CAR-T therapies, ongoing clinical trials, and its impact on clinical practice.
Overview of approved CAR-T therapies, ongoing clinical trials, and its impact on clinical practice.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
近年来，CAR-T 细胞疗法在多种恶性肿瘤中的应用迅速扩展，深刻改变了非霍奇金淋巴瘤、B细胞急性淋巴细胞白血病和多发性骨髓瘤的治疗格局。目前可用的CD19和B细胞成熟抗原靶向CAR-T 疗法，在标准治疗失败患者中显示出较高总缓解率和持久缓解。多项研究正在探索将CAR-T 前移至更早治疗线。在高级别B细胞淋巴瘤中，CD19 CAR-T 可能在不久的将来取代二线自体造血细胞移植。靶向新型肿瘤相关抗原的CAR-T 有助于将该疗法拓展至其他血液系统恶性肿瘤，也可能克服现有获批CAR-T 的局限。本综述概述目前获批的CAR-T 疗法及可能影响临床实践的后续临床试验。
In recent years, we have seen rapid expansion of chimeric antigen receptor T-cell (CAR-T) therapies in multiple malignancies. CAR-T therapy has profoundly altered the treatment landscape of non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia, and multiple myeloma. Currently available CD19 and B-cell maturation antigen-directed CAR-T therapies have shown high overall response rate and durable remissions in patients who have failed standard therapies. Multiple studies are underway exploring the role of CAR-T-cell therapy as earlier line of treatment.
In high-grade B-cell lymphoma, CD19 CAR-T therapy may replace autologous hematopoietic cell transplantation as second line therapy in near future. CAR-T-cell therapy targeting novel tumor-associated antigens will help expand utility of this treatment modality in other hematological malignancies. It may also help overcome limitations of currently approved CAR-T-cell therapies. In this review, we have provided an overview of currently approved CAR-T therapies and upcoming clinical trials which may potentially impact the clinical practice.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
